143999-83-1

Basic information

• Product Name: 2-(4-CHLORO-PHENOXY)-1-PIPERAZIN-1-YL-ETHANONE
• Synonyms: TIMTEC-BB SBB011990;2-(4-CHLORO-PHENOXY)-1-PIPERAZIN-1-YL-ETHANONE
• CAS NO: 143999-83-1
• Molecular Formula: C₁₂H₁₅ClN₂O₂
• Molecular Weight: 254.71
• Mol File: 143999-83-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 438.3°Cat760mmHg
• Flash Point: 218.9°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 6.99E-08mmHg at 25°C
• CAS DataBase Reference: 2-(4-CHLORO-PHENOXY)-1-PIPERAZIN-1-YL-ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-CHLORO-PHENOXY)-1-PIPERAZIN-1-YL-ETHANONE(143999-83-1)
• EPA Substance Registry System: 2-(4-CHLORO-PHENOXY)-1-PIPERAZIN-1-YL-ETHANONE(143999-83-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 143999-83-1(Hazardous Substances Data)

Usage

Description

2-(4-CHLORO-PHENOXY)-1-PIPERAZIN-1-YL-ETHANONE is a chemical compound characterized by the molecular formula C13H16ClN3O2. It is a derivative of piperazinyl-ethanone, featuring a piperazine ring and a chlorophenyl group. 2-(4-CHLORO-PHENOXY)-1-PIPERAZIN-1-YL-ETHANONE is frequently encountered in medicinal chemistry and pharmaceutical research, where it is recognized for its potential as a drug candidate. Its diverse biological activities and pharmacological properties make it a valuable subject for ongoing study and development.

Uses

Used in Pharmaceutical Research:
2-(4-CHLORO-PHENOXY)-1-PIPERAZIN-1-YL-ETHANONE is utilized as a potential drug candidate in pharmaceutical research for its possible biological activities and pharmacological properties. Its unique structure, which includes a piperazine ring and a chlorophenyl group, may contribute to its efficacy in treating various medical conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-(4-CHLORO-PHENOXY)-1-PIPERAZIN-1-YL-ETHANONE is employed for its potential to be developed into new therapeutic agents. Its chemical structure allows for modifications and optimizations that could enhance its pharmacological profile, making it a versatile compound for the development of novel drugs.

InChI:InChI=1/C12H15ClN2O2/c13-10-1-3-11(4-2-10)17-9-12(16)15-7-5-14-6-8-15/h1-4,14H,5-9H2/p+1

Upstream product

• 1144037-43-3 tert-butyl 4-(2-(4-chlorophenoxy)acetyl)piperazine-1-carboxylate 
• 110-85-0 piperazine 
• 14426-42-7 ethyl p-chlorophenoxyacetate 
• 106-48-9 4-chloro-phenol 
• 4122-68-3 4-chlorophenyloxyacetyl chloride 
• 122-88-3 4-Chlorophenoxyacetic acid 
• 1193-00-6 sodium 4-chlorophenolate 

Downstream Products

• 1217309-75-5 2-(4-chlorophenoxy)-1-(4-(6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)ethanone 
• 1217309-76-6 1-(4-(2-butyl-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)-2-(4-chlorophenoxy)ethanone 
• 1217309-83-5 2-(4-chlorophenoxy)-1-(4-(6-(4-fluorophenyl)-2-methylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)ethanone 
• 1217309-84-6 2-(4-chlorophenoxy)-1-(4-(6-(4-fluorophenyl)-2-phenylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)ethanone 
• 1217309-85-7 ethyl 4-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidine-2-carboxylate 
• 1245319-02-1 1-(4-(5-amino-2-(4-fluorophenyl)oxazolo[5,4-d]pyrimidin-7-yl)-piperazin-1-yl)-2-(4-chlorophenoxy)ethanone 
• 1245320-72-2 1-(4-(2-amino-8-(4-fluorophenyl)-9H-purin-6-yl)piperazin-1-yl)-2-(4-chlorophenoxy)ethanone 
• 1245317-06-9 1-(4-(5-amino-2-(4-fluorobenzyl)thiazolo[5,4-d]pyrimidin-7-yl)piperazin-1-yl)-2-(4-chlorophenoxy)ethanone 
• 1245317-11-6 1-(4-(5-amino-2-(2-(4-fluorophenoxy)ethyl)thiazolo[5,4-d]pyrimidin-7-yl)piperazin-1-yl)-2-(4-chlorophenoxy)ethanone 
• 1245317-37-6 1-(4-(5-amino-2-(1-(4-fluorophenyl)ethyl)thiazolo[5,4-d]pyrimidin-7-yl)piperazin-1-yl)-2-(4-chlorophenoxy)ethanone 
• 1245317-13-8 1-(4-(5-amino-2-(4-fluorophenethyl)-thiazolo[5,4-d]pyrimidin-7-yl)piperazin-1-yl)-2-(4-chlorophenoxy)ethanone 

Relevant articles and documents

BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION

The present invention relates to compounds comprising a benzimidazole scaffold, and the use of such compounds for the treatment of viral diseases. The invention also relates to pharmaceutical compositions comprising said compounds as an active ingredient. In particular the compounds of the invention comprising a benzimidazole scaffold are used for the treatment of filoviruses or retroviruses, and preferably for the treatment of Ebola virus or HIV virus.

ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES

The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, Formulas (I), (II), (III) and (IV) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of proliferative disorders and pathologic conditions such as, but not limited to, cancer such as leukemia.

THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS

The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1. The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections.